Abstract
"Cytokine storm" is a hallmark of severe COVID-19, yet the underlying mechanisms, particularly in extra-pulmonary organs like the kidney, remain poorly understood. This study demonstrates that overexpression of the SARS-CoV-2 Nucleocapsid (N) protein in diabetic db/db mice significantly exacerbates acute kidney injury (AKI). This injury is characterized by increased tubular cell death and the release of High Mobility Group Box 1 (HMGB1), a damage-associated molecular pattern (DAMP). HMGB1 subsequently triggers M1 proinflammatory macrophage activation and the production of cytokines (IL-6, TNF-α, MCP-1) via a Mincle-Syk/NF-κB-dependent signaling pathway. Crucially, treatment with the flavonoid quercetin was found to improve AKI by inhibiting HMGB1 release and suppressing the Mincle-Syk/NF-κB axis, thereby promoting a shift from pro-inflammatory M1 to reparative M2 macrophage responses.
Introduction: Beyond the Spike Protein
While much of the research on COVID-19 has focused on the viral Spike protein and its role in entry, the Nucleocapsid (N) protein is also a major structural component that plays a critical role in viral replication and host immune evasion. Patients with pre-existing conditions, particularly diabetes, are at a significantly higher risk for severe complications like acute kidney injury (AKI). This study investigates the synergy between diabetic conditions and the SARS-CoV-2 N protein in driving renal damage.
The researchers hypothesized that the N protein, in the presence of high advanced glycation end-products (AGEs) typical of diabetes, triggers a "cytokine storm" within the kidney. They specifically looked at how injured kidney cells communicate with the immune system through "danger signals" or DAMPs, leading to maladaptive immune responses.
The Mincle-Syk/NF-κB Signaling Pathway
A key discovery of this work is the identification of the Mincle-Syk/NF-κB signaling axis as the primary driver of macrophage-mediated inflammation in this model. Mincle (Macrophage-inducible C-type lectin) acts as a sensor for HMGB1, a protein released by dying tubular epithelial cells.
When the N protein is overexpressed in a diabetic environment, it accelerates tubular cell death and HMGB1 leakage. HMGB1 binds to Mincle on the surface of macrophages, activating the Syk (Spleen tyrosine kinase) and NF-κB (Nuclear factor kappa B) pathways. This activation "reprograms" macrophages into an aggressive M1 phenotype, which floods the kidney with pro-inflammatory cytokines like IL-6 and TNF-α, further exacerbating tissue damage.
Experimental Evidence
The study utilized a combination of in vivo diabetic mouse models (db/db mice) and in vitro cell cultures. To isolate the effects of the viral protein, the researchers used ultrasound-microbubble-mediated gene transfer to specifically overexpress the SARS-CoV-2 N protein in the kidneys of 16-week-old mice.
Key findings include:
- Exacerbated Renal Dysfunction: N protein overexpression in diabetic mice led to a marked increase in serum creatinine and blood urea nitrogen (BUN) levels compared to non-diabetic controls or diabetic mice without the N protein.
- Macrophage Polarization: Flow cytometry and immunofluorescence revealed a significant shift toward the M1 phenotype (Mincle+/CD68+ and iNOS+/CD68+) in the kidneys of N-protein-treated diabetic mice.
- Cytokine Surge: mRNA levels of IL-6, TNF-α, and MCP-1 were significantly elevated, mirroring the "cytokine storm" seen in clinical cases.
Quercetin as a Therapeutic Strategy
Perhaps the most significant finding is the therapeutic potential of quercetin, a natural flavonoid. Quercetin was shown to effectively intercept the inflammatory cascade at multiple levels.
As shown in Figure 6, the N protein (NP) significantly upregulates both HMGB1 and Mincle expression in the diabetic kidney. Quercetin (QUE) treatment markedly reduced these levels, effectively silencing the "danger signal" and its receptor. Mechanistically, quercetin inhibits the release of HMGB1 from injured tubules and inactivates the Mincle-Syk/NF-κB pathway in macrophages. This not only reduces M1-driven inflammation but also promotes the emergence of reparative M2 macrophages, aiding in tissue recovery.
Conclusion and Future Directions
This study provides a molecular blueprint for how the SARS-CoV-2 N protein drives AKI in diabetic patients. By identifying Mincle as a critical sensor for viral-induced damage, it opens new avenues for targeted therapy. Quercetin, by suppressing this axis, offers a promising, readily available intervention to mitigate severe COVID-19 complications.
However, limitations remain. The use of gene transfer to express the N protein does not fully replicate the dynamics of a systemic viral infection. Furthermore, while the results in db/db mice are compelling, clinical trials are essential to determine if these findings translate to human patients and to establish optimal dosing regimens. Future research should also investigate whether early intervention in this pathway can prevent the long-term transition from AKI to chronic kidney disease (CKD) in COVID-19 survivors.
Summary updated